查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1947837

T细胞疗法市场分析及预测（至2035年）：依类型、产品、服务、技术、应用、最终使用者、流程、阶段及解决方案划分

T-cell Therapy Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Process, Stage, Solutions
出版日期: | 出版商: Global Insight Services | 英文 341 Pages | 商品交期: 3-5个工作天内

价格
简介目录

T细胞疗法市场预计将从2024年的52亿美元成长到2034年的582亿美元，复合年增长率约为29.1%。 T细胞治疗方法市场利用基因工程改造的T细胞来增强免疫反应，并调动人体自身的免疫系统来靶向和摧毁癌细胞。 CAR-T和TCR疗法的进步是推动该市场成长的主要因素，这些疗法能够提供个人化医疗，并展现出良好的疗效。儘管癌症发病率的上升和技术创新正在推动市场成长，但高成本和复杂的生产流程仍然是该市场面临的挑战。

在癌症治疗和个人化医疗的推动下，T细胞疗法市场持续强劲成长。 CAR-T细胞疗法是其中表现最强的细分市场，这主要得益于其在治疗骨髓恶性肿瘤的成功。该领域的创新提高了疗效和安全性，吸引了大量投资。 TCR-T细胞疗法是表现第二强劲的细分市场，因其靶向固态肿瘤的潜力而备受关注。正在进行的临床试验和令人鼓舞的早期结果进一步巩固了该细分市场的地位。异体T细胞疗法已成为重点领域，与自体疗法相比，它具有扩充性和更短的生产週期。同时，自体T细胞疗法因其个人化治疗方案和已建立的临床疗效而依然重要。生技公司和研究机构之间日益密切的合作正在加速研发进程。监管政策的进步也进一步推动了市场成长，为相关人员创造了盈利的机会。

市场区隔
类型 CAR-T细胞疗法、TCR疗法、TIL疗法
产品 自製产品、类似产品
服务 製造服务、物流服务、咨询服务
科技 基因编辑、细胞增生、细胞分离
应用领域 肿瘤学、感染疾病、自体免疫疾病
最终用户 医院、癌症研究中心和生物技术公司
流程 外生物过程，内生物过程
介绍 临床试验和商业部署
功能 治疗和诊断
解决方案 客製化T细胞解决方案，标准化T细胞解决方案

T细胞疗法市场正经历显着的变革，市占率主要由少数几家主要企业主导。由于新参与企业和创新产品的不断涌现，定价策略竞争日益激烈。新型治疗方法的推出正在重塑市场格局，并推动市场兴趣和投资。各公司正致力于个人化医疗，以改善患者疗效并扩大治疗覆盖范围。这种充满活力的市场环境正在催生出强大的下一代T细胞疗法研发管线，以满足尚未满足的医疗需求。 T细胞疗法市场的竞争日益激烈，各公司竞相争夺技术优势。基准分析表明，投资专有技术和策略联盟的公司正在获得竞争优势。监管的影响至关重要，严格的指导方针规范产品开发和市场准入。美国食品药物管理局（FDA）和欧洲药品管理局（EMA）是影响全球标准的关键监管机构。市场分析强调了有效利用这些法规结构对于确保成功商业化和永续成长的重要性。对于能够巧妙运用技术进步和监管洞察的公司而言，这个市场环境充满机会。

主要趋势和驱动因素：

受免疫疗法和个人化医疗进步的推动，T细胞疗法市场正经历强劲成长。关键趋势包括CAR-T细胞疗法的日益普及，在治疗骨髓恶性肿瘤展现出显着疗效。探索T细胞疗法治疗固体癌的临床试验不断扩展，这是一项重要进展，有望推动其更广泛的应用并改善患者预后。推动市场成长的因素包括癌症发生率的上升以及对创新治疗方法的迫切需求。监管支持和加速核准流程也促进了新型治疗方法进入市场。此外，生技公司与学术机构之间的合作正在加速研发进程，推动T细胞设计和製造技术的突破。新兴市场蕴藏着大量机会，这些市场医疗基础设施的改善和生物技术领域投资的增加为T细胞疗法的引入创造了有利条件。能够顺利通过监管审批流程并建立成本效益高的生产流程的公司，将更有机会在这个不断扩大的市场中占据优势。此外，基因编辑技术和人工智慧的进步正在提高T细胞疗法的精确性和有效性，进一步推动市场发展。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章 细分市场分析

  • 市场规模及预测：依类型
    • CAR-T细胞疗法
    • TCR疗法
    • TIL疗法
    • 其他的
  • 市场规模及预测：依产品划分
    • 自製产品
    • 同种异体移植产品
    • 其他的
  • 市场规模及预测：依服务划分
    • 製造服务
    • 物流服务
    • 咨询服务
    • 其他的
  • 市场规模及预测：依技术划分
    • 基因编辑
    • 细胞增殖
    • 细胞分离
    • 其他的
  • 市场规模及预测：依应用领域划分
    • 肿瘤学
    • 感染疾病
    • 自体免疫疾病
    • 其他的
  • 市场规模及预测：依最终用户划分
    • 医院
    • 癌症研究中心
    • 生技公司
    • 其他的
  • 市场规模及预测：依製程划分
    • 体外处理
    • 生物过程
    • 其他的
  • 市场规模及预测：依发展状况
    • 临床试验
    • 商业部署
    • 其他的
  • 市场规模及预测：依功能划分
    • 治疗
    • 诊断
    • 其他的
  • 市场规模及预测：按解决方案划分
    • 客製化T细胞解决方案
    • 标准化T细胞溶液
    • 其他的

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 其他亚太地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 需求与供给差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 法规概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章 公司简介

  • Adaptimmune Therapeutics
  • Atara Biotherapeutics
  • Autolus Therapeutics
  • Bellicum Pharmaceuticals
  • Bluebird Bio
  • Cellectis
  • Celularity
  • Genocea Biosciences
  • Iovance Biotherapeutics
  • Kiadis Pharma
  • Marker Therapeutics
  • Mustang Bio
  • Poseida Therapeutics
  • Sorrento Therapeutics
  • TCR2 Therapeutics
  • Tessa Therapeutics
  • Turnstone Biologics
  • Unum Therapeutics
  • Ziopharm Oncology
  • Celyad Oncology

第九章：关于我们

简介目录
Product Code: GIS21392

T-cell Therapy Market is anticipated to expand from $5.2 billion in 2024 to $58.2 billion by 2034, growing at a CAGR of approximately 29.1%. The T-cell Therapy Market encompasses treatments that harness the body's immune system to target and destroy cancer cells, utilizing engineered T-cells to enhance immune response. This market is driven by advancements in CAR-T and TCR therapies, offering personalized medicine with promising efficacy. Increasing cancer prevalence and technological innovations are propelling growth, while challenges include high costs and complex manufacturing processes.

The T-cell Therapy Market is experiencing robust expansion, driven by advancements in cancer treatment and personalized medicine. The CAR-T cell therapy segment leads in performance, due to its success in treating hematological malignancies. Innovations in this segment are enhancing efficacy and safety profiles, attracting significant investment. The second highest performing segment is TCR-T cell therapy, which is gaining traction for its potential in targeting solid tumors. This segment is bolstered by ongoing clinical trials and promising early results. The allogeneic T-cell therapy sub-segment is emerging as a key area of interest, offering scalability and reduced production times compared to autologous therapies. Meanwhile, the autologous T-cell therapy sub-segment remains relevant, benefiting from its customized approach and established clinical outcomes. Increasing collaboration between biotech firms and research institutions is accelerating development timelines. Regulatory advancements are further facilitating market growth, creating lucrative opportunities for stakeholders.

Market Segmentation
TypeCAR-T Cell Therapy, TCR Therapy, TIL Therapy
ProductAutologous Products, Allogeneic Products
ServicesManufacturing Services, Logistics Services, Consulting Services
TechnologyGene Editing, Cell Expansion, Cell Isolation
ApplicationOncology, Infectious Diseases, Autoimmune Disorders
End UserHospitals, Cancer Research Centers, Biotechnology Companies
ProcessEx Vivo Process, In Vivo Process
DeploymentClinical Trials, Commercial Deployment
FunctionalityTherapeutic, Diagnostic
SolutionsCustom T-Cell Solutions, Standardized T-Cell Solutions

The T-cell therapy market is witnessing significant evolution, with market share being predominantly held by a few key players. Pricing strategies are becoming more competitive due to the influx of new entrants and innovative product launches. The introduction of novel therapies is reshaping the landscape, driving interest and investment. Companies are focusing on personalized medicine, enhancing patient outcomes and expanding the therapeutic scope. This dynamic environment is fostering a robust pipeline of next-generation T-cell therapies poised to address unmet medical needs. Competition in the T-cell therapy market is intensifying, with firms vying for technological superiority. Benchmarking reveals that companies investing in proprietary technologies and strategic collaborations are gaining a competitive edge. Regulatory influences are pivotal, with stringent guidelines shaping product development and market entry. The U.S. FDA and European Medicines Agency are leading regulatory bodies influencing global standards. The market analysis emphasizes the importance of navigating these regulatory frameworks to ensure successful commercialization and sustained growth. The landscape is ripe with opportunities for those adept at leveraging technological advancements and regulatory insights.

Geographical Overview:

The T-cell therapy market is witnessing robust growth across various regions, each presenting unique opportunities. North America leads the market, driven by advanced healthcare infrastructure and substantial investments in biotechnology. The presence of leading pharmaceutical companies and a strong focus on research and development further bolster the region's dominance. Europe follows, with significant investments in healthcare innovation fostering a thriving market for T-cell therapies. The region's regulatory environment supports clinical trials and accelerates the approval process, enhancing market growth. In Asia Pacific, the market is expanding rapidly, fueled by increasing healthcare expenditure and government initiatives promoting advanced therapies. Emerging countries like China and India are becoming vital growth pockets, with rising demand for innovative cancer treatments. Latin America and the Middle East & Africa are also gaining traction. These regions are recognizing the potential of T-cell therapies in addressing unmet medical needs and are investing in healthcare infrastructure to support market expansion.

The T-cell Therapy Market is navigating complex geopolitical landscapes and supply chain challenges, particularly in Japan, South Korea, China, and Taiwan. Global tariffs and trade tensions have necessitated strategic pivots in these nations, with Japan and South Korea enhancing domestic biomanufacturing capabilities to mitigate reliance on foreign imports. China is accelerating its biopharmaceutical innovation, seeking self-sufficiency amidst export restrictions. Taiwan, while a pivotal player in biotechnological advancements, faces geopolitical vulnerabilities due to US-China frictions. The parent market is experiencing robust growth globally, driven by advancements in personalized medicine and increasing cancer prevalence. By 2035, the market is expected to flourish, contingent on resilient supply chains and international collaborations. Middle East conflicts could indirectly affect supply chains through volatile energy prices, impacting operational costs and timelines.

Key Trends and Drivers:

The T-cell therapy market is experiencing robust growth, propelled by advancements in immunotherapy and personalized medicine. Key trends include the increasing adoption of CAR-T cell therapies, which have shown remarkable efficacy in treating hematological malignancies. The expansion of clinical trials exploring T-cell therapies for solid tumors marks a significant development, promising broader applications and improved patient outcomes. Drivers of market growth encompass the rising prevalence of cancer and the urgent need for innovative treatment options. Regulatory support and expedited approval processes are also facilitating the rapid entry of new therapies into the market. Additionally, collaborations between biotechnology firms and academic institutions are accelerating research and development efforts, leading to breakthroughs in T-cell engineering and manufacturing. Opportunities abound in emerging markets, where healthcare infrastructure improvements and growing investment in biotechnology are creating fertile ground for T-cell therapy adoption. Companies that can navigate regulatory pathways and establish cost-effective production processes are well-positioned to capitalize on these expanding markets. Furthermore, advancements in gene editing technologies and artificial intelligence are set to enhance the precision and efficacy of T-cell therapies, driving the market forward.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Process
  • 2.8 Key Market Highlights by Deployment
  • 2.9 Key Market Highlights by Functionality
  • 2.10 Key Market Highlights by Solutions

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 CAR-T Cell Therapy
    • 4.1.2 TCR Therapy
    • 4.1.3 TIL Therapy
    • 4.1.4 Others
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Autologous Products
    • 4.2.2 Allogeneic Products
    • 4.2.3 Others
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Manufacturing Services
    • 4.3.2 Logistics Services
    • 4.3.3 Consulting Services
    • 4.3.4 Others
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Gene Editing
    • 4.4.2 Cell Expansion
    • 4.4.3 Cell Isolation
    • 4.4.4 Others
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Oncology
    • 4.5.2 Infectious Diseases
    • 4.5.3 Autoimmune Disorders
    • 4.5.4 Others
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Hospitals
    • 4.6.2 Cancer Research Centers
    • 4.6.3 Biotechnology Companies
    • 4.6.4 Others
  • 4.7 Market Size & Forecast by Process (2020-2035)
    • 4.7.1 Ex Vivo Process
    • 4.7.2 In Vivo Process
    • 4.7.3 Others
  • 4.8 Market Size & Forecast by Deployment (2020-2035)
    • 4.8.1 Clinical Trials
    • 4.8.2 Commercial Deployment
    • 4.8.3 Others
  • 4.9 Market Size & Forecast by Functionality (2020-2035)
    • 4.9.1 Therapeutic
    • 4.9.2 Diagnostic
    • 4.9.3 Others
  • 4.10 Market Size & Forecast by Solutions (2020-2035)
    • 4.10.1 Custom T-Cell Solutions
    • 4.10.2 Standardized T-Cell Solutions
    • 4.10.3 Others

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Process
      • 5.2.1.8 Deployment
      • 5.2.1.9 Functionality
      • 5.2.1.10 Solutions
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Process
      • 5.2.2.8 Deployment
      • 5.2.2.9 Functionality
      • 5.2.2.10 Solutions
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Process
      • 5.2.3.8 Deployment
      • 5.2.3.9 Functionality
      • 5.2.3.10 Solutions
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Process
      • 5.3.1.8 Deployment
      • 5.3.1.9 Functionality
      • 5.3.1.10 Solutions
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Process
      • 5.3.2.8 Deployment
      • 5.3.2.9 Functionality
      • 5.3.2.10 Solutions
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Process
      • 5.3.3.8 Deployment
      • 5.3.3.9 Functionality
      • 5.3.3.10 Solutions
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Process
      • 5.4.1.8 Deployment
      • 5.4.1.9 Functionality
      • 5.4.1.10 Solutions
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Process
      • 5.4.2.8 Deployment
      • 5.4.2.9 Functionality
      • 5.4.2.10 Solutions
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Process
      • 5.4.3.8 Deployment
      • 5.4.3.9 Functionality
      • 5.4.3.10 Solutions
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Process
      • 5.4.4.8 Deployment
      • 5.4.4.9 Functionality
      • 5.4.4.10 Solutions
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Process
      • 5.4.5.8 Deployment
      • 5.4.5.9 Functionality
      • 5.4.5.10 Solutions
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Process
      • 5.4.6.8 Deployment
      • 5.4.6.9 Functionality
      • 5.4.6.10 Solutions
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Process
      • 5.4.7.8 Deployment
      • 5.4.7.9 Functionality
      • 5.4.7.10 Solutions
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Process
      • 5.5.1.8 Deployment
      • 5.5.1.9 Functionality
      • 5.5.1.10 Solutions
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Process
      • 5.5.2.8 Deployment
      • 5.5.2.9 Functionality
      • 5.5.2.10 Solutions
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Process
      • 5.5.3.8 Deployment
      • 5.5.3.9 Functionality
      • 5.5.3.10 Solutions
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Process
      • 5.5.4.8 Deployment
      • 5.5.4.9 Functionality
      • 5.5.4.10 Solutions
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Process
      • 5.5.5.8 Deployment
      • 5.5.5.9 Functionality
      • 5.5.5.10 Solutions
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Process
      • 5.5.6.8 Deployment
      • 5.5.6.9 Functionality
      • 5.5.6.10 Solutions
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Process
      • 5.6.1.8 Deployment
      • 5.6.1.9 Functionality
      • 5.6.1.10 Solutions
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Process
      • 5.6.2.8 Deployment
      • 5.6.2.9 Functionality
      • 5.6.2.10 Solutions
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Process
      • 5.6.3.8 Deployment
      • 5.6.3.9 Functionality
      • 5.6.3.10 Solutions
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Process
      • 5.6.4.8 Deployment
      • 5.6.4.9 Functionality
      • 5.6.4.10 Solutions
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Process
      • 5.6.5.8 Deployment
      • 5.6.5.9 Functionality
      • 5.6.5.10 Solutions

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Adaptimmune Therapeutics
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Atara Biotherapeutics
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Autolus Therapeutics
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Bellicum Pharmaceuticals
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Bluebird Bio
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Cellectis
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Celularity
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Genocea Biosciences
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Iovance Biotherapeutics
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Kiadis Pharma
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Marker Therapeutics
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Mustang Bio
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Poseida Therapeutics
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Sorrento Therapeutics
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 TCR2 Therapeutics
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Tessa Therapeutics
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Turnstone Biologics
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Unum Therapeutics
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Ziopharm Oncology
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Celyad Oncology
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us